These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35228895)

  • 1. CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade.
    Zheng A; Du Y; Wang Y; Zheng Y; Ning Z; Wu M; Zhang C; Zhang D; Liu J; Liu X
    Mol Ther Nucleic Acids; 2022 Mar; 27():998-1009. PubMed ID: 35228895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo.
    An Y; Li X; Yao F; Duan J; Yang XD
    Molecules; 2022 Feb; 27(5):. PubMed ID: 35268583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A highly stable multifunctional aptamer for enhancing antitumor immunity against hepatocellular carcinoma by blocking dual immune checkpoints.
    Du Y; Zhang D; Wang Y; Wu M; Zhang C; Zheng Y; Zheng A; Liu X
    Biomater Sci; 2021 Jun; 9(11):4159-4168. PubMed ID: 33970170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
    Hsu J; Hodgins JJ; Marathe M; Nicolai CJ; Bourgeois-Daigneault MC; Trevino TN; Azimi CS; Scheer AK; Randolph HE; Thompson TW; Zhang L; Iannello A; Mathur N; Jardine KE; Kirn GA; Bell JC; McBurney MW; Raulet DH; Ardolino M
    J Clin Invest; 2018 Oct; 128(10):4654-4668. PubMed ID: 30198904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK cells and ILCs in tumor immunotherapy.
    Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
    Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
    Shaver KA; Croom-Perez TJ; Copik AJ
    Front Immunol; 2021; 12():679117. PubMed ID: 33995422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gold-seaurchin based immunomodulator enabling photothermal intervention and αCD16 transfection to boost NK cell adoptive immunotherapy.
    Lin X; Li F; Gu Q; Wang X; Zheng Y; Li J; Guan J; Yao C; Liu X
    Acta Biomater; 2022 Jul; 146():406-420. PubMed ID: 35470078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 11. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.
    Cichocki F; Bjordahl R; Gaidarova S; Mahmood S; Abujarour R; Wang H; Tuininga K; Felices M; Davis ZB; Bendzick L; Clarke R; Stokely L; Rogers P; Ge M; Robinson M; Rezner B; Robbins DL; Lee TT; Kaufman DS; Blazar BR; Valamehr B; Miller JS
    Sci Transl Med; 2020 Nov; 12(568):. PubMed ID: 33148626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 blockade enhances anti-tumor efficacy of NK cells.
    Oyer JL; Gitto SB; Altomare DA; Copik AJ
    Oncoimmunology; 2018; 7(11):e1509819. PubMed ID: 30377572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 aptamer-functionalized degradable hafnium oxide nanoparticles for near infrared-II diagnostic imaging and radiosensitization.
    Wei M; Shen X; Fan X; Li J; Bai J
    Front Bioeng Biotechnol; 2023; 11():1224339. PubMed ID: 37351473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
    Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
    ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
    Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer.
    Zhao W; Jia L; Zhang M; Huang X; Qian P; Tang Q; Zhu J; Feng Z
    Am J Cancer Res; 2019; 9(8):1846-1856. PubMed ID: 31497363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
    Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
    Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.